Abstract
Purpose: Adult articular cartilage has a limited ability for self-healing in response to injury. Gene transfer using the clinically adapted recombinant adeno-associated virus (rAAV) vector is a powerful tool for cartilage repair [1] but the pre-existence of neutralizing antibodies against viral capsid epitopes in patients may impede gene transfer in vivo [2]. To circumvent such a barrier, we tested the feasibility of delivering therapeutic (chondrogenic sox9 and TGF-β) rAAV vectors in reparative human bone marrow aspirates by vector delivery using poly(sodium styrene sulfonate) (pNaSS)-grafted poly(ε-caprolactone) (PCL) films for implantation in a human osteochondral defect model as a potential scaffold-guided gene therapy option [1].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
